PROMETHERA BIOSCIENCES
Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):
PROMETHERA BIOSCIENCES
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2009-01-01
Address:
Mont-saint-guibert, Brabant Wallon, Belgium
Country:
Belgium
Website Url:
http://www.promethera.com
Total Employee:
101+
Status:
Active
Contact:
32 1 039 43 00
Email Addresses:
[email protected]
Total Funding:
149.1 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Vimeo GlobalSign Domain Verification Vimeo CDN DocuSign Symantec.cloud Exclaimer Equinix
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2018-04-10 | Baliopharm | Baliopharm acquired by Promethera Biosciences | N/A |
Investors List
Pegasus Tech Ventures
Pegasus Tech Ventures investment in Series D - Promethera Biosciences
Sony Innovation Fund
Sony Innovation Fund investment in Series D - Promethera Biosciences
ITOCHU Technology Ventures
ITOCHU Technology Ventures investment in Series D - Promethera Biosciences
Sansei Capital Investment
Sansei Capital Investment investment in Series D - Promethera Biosciences
Shibuya Kogyo
Shibuya Kogyo investment in Convertible Note - Promethera Biosciences
Shinsei Corporate Investment
Shinsei Corporate Investment investment in Convertible Note - Promethera Biosciences
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series C - Promethera Biosciences
Vesalius Biocapital Partners
Vesalius Biocapital Partners investment in Series C - Promethera Biosciences
Fund+
Fund+ investment in Series C - Promethera Biosciences
Mitsubishi UFJ Capital
Mitsubishi UFJ Capital investment in Series C - Promethera Biosciences
Key Employee Changes
| Date | New article |
|---|---|
| 2019-12-11 | Prometheus Bio Taps Thierry Dervieux as Chief Development Officer |
Official Site Inspections
http://www.promethera.com
- Host name: 217.19.237.54.static.hosted.by.combell.com
- IP address: 217.19.237.54
- Location: Brussels Belgium
- Latitude: 50.8336
- Longitude: 4.3337
- Timezone: Europe/Brussels
- Postal: 1060
More informations about "Promethera Biosciences"
Promethera Biosciences - Crunchbase Company Profile …
When was the last funding round for Promethera Biosciences? Promethera Biosciences closed its last funding round on Dec 16, 2019 from a Series D …See details»
Novabiosis Inc. and Promethera Therapeutics Joint …
RESEARCH TRIANGLE PARK, NC. and MONT-SAINT-GUIBERT, BELGIUM – October 6 th 2021 — Promethera Therapeutics SA, a pioneer in cell therapies for treatment of severe liver diseases, has divested certain assets of their US …See details»
The new Walloon company Cellaïon - cellaion.com
Jan 18, 2022 With this transaction, the technological platform and the assets of the former Promethera company return entirely to the Belgian -Luxembourg fold. Cellaïon aims at the …See details»
Cellaïon
Any downfall of its functioning leads to failure of other vital organs and ultimately death. With HepaStem®, Cellaïon aims to stop the progression of chronic liver disease, control …See details»
Promethera Biosciences Company Profile - Craft
Promethera Biosciences is a healthcare company developing cell therapy technologies for chronic liver diseases. It has treatment programs derived from both its proprietary technologies and …See details»
More documents for Promethera (Group) - Life-Sciences …
Promethera® Therapeutics SA is a global innovator in the treatment of liver diseases, whose mission is to offer patients high technology treatments to increase their chance of survival and …See details»
Promethera Biosciences - VentureRadar
Develops innovative cell-based therapies aimed at treating a wide range of liver diseases, utilizing cutting-edge research and technology. "Promethera® Biosciences is a Belgian pharmaceutical …See details»
Promethera Biosciences - Products, Competitors, Financials, …
Promethera Biosciences primarily serves the healthcare sector, with a focus on liver therapeutics. It was founded in 2009 and is based in Mont Saint Guibert, Belgium. Headquarters Location. …See details»
Promethera Biosciences - Funding, Financials, Valuation & Investors
Promethera Biosciences has acquired Baliopharm on Apr 10, 2018. Unlock for free . Funding Rounds. Edit Funding Rounds Section. Number of Funding Rounds 7. ... How much funding …See details»
Promethera Biosciences - Contacts, Employees, Board Members, …
Promethera Biosciences is a biopharmaceutical company focused on cell therapy products to treat liver diseases.See details»
HepaStem: toward an alternative to liver transplantation - Nature
Alexandra Schiettekatte, Global Associate Director Communications, Promethera Biosciences SA/NV, Mont-Saint-Guibert, Belgium, Tel: +32 10 39 43 00, Website: www.promethera.com …See details»
Promethera® Plans to Form Joint Venture to Conduct ... - Business …
Jul 16, 2020 For Promethera ® Biosciences SA: ALEXANDRA SCHIETTEKATTE – Global Senior Director Communications [email protected] For Media - MacDougall: MARIO …See details»
Promethera ® Announces Changes in Executive Leadership
Sep 2, 2020 Contacts. For Promethera Biosciences SA: ALEXANDRA SCHIETTEKATTE – Global Director Communications & Spokesperson [email protected] …See details»
Walloon company Promethera announces a € 20 millions …
Jun 30, 2021 Mont-Saint-Guibert, Belgium, 30th June 2021 – Promethera Therapeutics SA, a pioneer in cell therapies for severe liver diseases, today announces a financing agreement for …See details»
Catalent acquires Promethera subsidiary to further
May 7, 2021. Article. Will use new facility in Belgium for commercial production of plasmid DNA. Contract development and manufacturing organization Catalent has acquired Promethera …See details»
Promethera Biosciences Announces Investment by ITOCHU …
Jan 2, 2019 Promethera Biosciences is a global innovator in liver therapeutics whose mission is to enable patients to overcome acute and chronic liver diseases. Our lead clinical program, …See details»
Targeting NASH and other devastating fibro-inflammatory liver …
Alexandra Schiettekatte, Global Associate Director Communications, Promethera Biosciences SA/NV, Mont-Saint-Guibert, Belgium, Tel: +32 10 39 43 00, Website: www.promethera.com …See details»
Hepatocyte cell therapy (Heparesc) - Cellaion - AdisInsight
Feb 17, 2022 29 Aug 2018 Hepatocyte cell therapy (Heparesc) - Promethera Biosciences is available for licensing in Canada as of 16 Jan 2020. www.promethera.com 05 Oct 2017 …See details»
Promethera raises €40M to fund trial of NASH cell therapy
May 6, 2019 Promethera Biosciences has raised €39.7 million ($44.4 million) to put its liver disease cell therapy through clinical trials. The series D round comes as Promethera prepares …See details»
Immunoprivileged: why liver-derived stem cells are the key to ...
Promethera is developing HepaStem, a unique cell therapy that expresses mesenchymal stem cells with immunomodulatory properties suitable for the treatment of a number of hepatic …See details»